ALK and non-small cell lung carcinoma: In addition, the ALINA trial results demonstrated that alectinib therapy significantly improved DFS in patients with completely resected NSCLC harboring anaplastic lymphoma kinase (ALK) rearrangement compared to standard adjuvant chemotherapy (12).